Anika Therapeutics
ANIK
162 hedge funds and large institutions have $542M invested in Anika Therapeutics in 2016 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 61 increasing their positions, 54 reducing their positions, and 14 closing their positions.
71% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 14
57% more call options, than puts
Call options by funds: $2.38M | Put options by funds: $1.51M
14% more capital invested
Capital invested by funds: $475M → $542M (+$67.7M)
13% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 54
7% more funds holding
Funds holding: 152 → 162 (+10)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$7.6M |
| 2 |
FAM
Fred Alger Management
New York
|
+$5.63M |
| 3 |
CM
Capital Management
Glen Allen,
Virginia
|
+$4.76M |
| 4 |
HP
HealthInvest Partners
Stockholm,
Sweden
|
+$4.53M |
| 5 |
NAP
New Amsterdam Partners
New York
|
+$4.39M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
-$14.5M |
| 2 |
CSC
Cove Street Capital
El Segundo,
California
|
-$12.9M |
| 3 |
LCP
Lombardia Capital Partners
Pasadena,
California
|
-$8.83M |
| 4 |
TSW
Thompson Siegel & Walmsley
Richmond,
Virginia
|
-$8.67M |
| 5 |
Millennium Management
New York
|
-$4.22M |
ANIK Hedge Fund Activity: Q1 2016 in Review
162 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Anika Therapeutics (ANIK) for Q1 2016, worth a combined $542M — up 14% from $475M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new ANIK positions and 14 closed out — a net gain of 10 holders — while 61 added to existing stakes and 54 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $7.6M. The largest seller was Portolan Capital Management, cutting an estimated $14.5M.
- 162 institutional investors held Anika Therapeutics (ANIK) as of Q1 2016, up from 152 in Q4 2015.
- Funds reported $542M of Anika Therapeutics stock for Q1 2016, up 14% quarter-over-quarter.
- 24 funds opened new Anika Therapeutics positions in Q1 2016 and 14 closed out, a net change of +10 holders.
- The largest Anika Therapeutics buyer in Q1 2016 was Renaissance Technologies, an estimated $7.6M added.
- The largest Anika Therapeutics seller in Q1 2016 was Portolan Capital Management, an estimated $14.5M sold.
Based on aggregated 13F filings for Q1 2016.